Xiang Li

Dr. Xiang Li


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2025 in International Journal of Surgery
Verified
Journal Article
Open access
KFKun Fang
Kun Fang
YZYuhang Zhou
Yuhang Zhou
SWShuo Wu
Shuo Wu
DLDapeng Li
Dapeng Li
XCXiaoli Cui
Xiaoli Cui
CLChang Liu
Chang Liu
Background: Early studies found common metabolic reprogramming in breast cancer. However, the causal effects of plasma metabolites on breast cancer remain unclear. Methods: Mendelian randomization (MR) and linkage disequilibrium score (LDSC) regression were performed based on previously published genome-wide association study (GWAS) summary statistics. The robustness of the causal inference was validated by sensitivity analyses. Gene mapping was performed by combining significant single-nucleotide polymorphisms (SNPs) and expression quantitative trait loci (eQTL) data to obtain the related gene set. Immune-related genes were identified by bulk and single-cell RNA analyses. Clinical samples were used for validation. Results: After correction and sensitivity analysis, seven significant plasma metabolites were identified. LDSC did not detect significant genetic correlations. Mapping SNPs to genes showed that two genes (SPP1 and ADM2) were significantly upregulated in breast cancer. However, only SPP1 passed external cohort validation. Similar results were obtained in the single-cell RNA analysis. In addition, SPP1 was found to be more highly expressed in monocytes. In clinical samples of breast cancer, we verified the high expression of SPP1 in monocytes–macrophages. At the cellular level, the high expression of SPP1 in monocytes–macrophages can promote malignant phenotypes such as proliferation and migration of breast cancer cells, and its expression level is regulated by myristic acid in significantly differential plasma metabolites. Conclusion: The findings provided valuable insight for the development of personalized treatment strategies for breast cancer and indicate that SPP1 may be a therapeutic target.

12 March 2026 in Biological Research
Verified
Journal Article
Open access
PDF file
SWShuo Wu
Shuo Wu
YSYuexuan Su
Yuexuan Su
RZRuishan Zhang
Ruishan Zhang
YWYuying Wang
Yuying Wang
XLXiang Li
Xiang Li
Background: Metabolic alterations are key factors driving the development of breast cancer. Among them, metabolic reprogramming is an important biological hallmark of breast cancer. It is crucial to gain in-depth understanding of the relevant mechanisms and find effective treatment strategies. Isoimperatorin (ISO), a natural furanocoumarin, exhibits various pharmacological effects such as anti-inflammatory and antiviral activities. However, the impact of ISO on the growth of breast cancer cells and its underlying mechanisms remain unclear. Methods: Cell culture, transfection, and animal experiments were employed. CCK -8, colony formation, and flow cytometry were used to detect cell proliferation, apoptosis, and ROS levels. miRNA-Seq, qRT-PCR, and Western Blotting were applied to analyze gene and protein expression. Results: ISO inhibited breast cancer cell proliferation, induced apoptosis and ROS accumulation, and suppressed the Warburg effect. ISO upregulated miR- 874-3p, which directly targeted the 3′-UTR of POU2F1, inhibiting the transcriptional activation of key glycolytic genes. Blocking this axis reversed ISO’s tumor-suppressive effects in vitro and in vivo. Conclusion: This study first reveals a novel mechanism by which ISO regulates breast cancer metabolism and apoptosis via the miR-874-3p/POU2F1 axis, highlighting ISO’s potential as a dual metabolic-redox intervention agent and providing a new combined therapeutic target for breast cancer.